Comunicados de prensa

Showing 1‐20 of 500

03 de abr. de 2025

Lonza Publishes Invitation to the 2025 Annual General Meeting and 2024 Annual and Sustainability Reports

Annual General Meeting will take place on 9 May 2025 at the Congress Center in Basel, Switzerland Jean-Marc Huët proposed for re-election as Chair of the Board of Directors...

01 de abr. de 2025

Lonza Implements its Simplified and Streamlined Operating Model

Lonza’s new simplified and streamlined operating model is designed to support its One Lonza vision and strategy Previous divisional structure is now replaced with three newly...

01 de abr. de 2025

Lonza Completes its Share Buyback Program

Basel, Switzerland, 1 April 2025 – Lonza today announced the successful completion of its share buyback program of up to CHF 2 billion which was launched on 3 April 2023. Gracias...

29 de ene. de 2025

Lonza Delivers Solid 2024 Performance with CER Sales in Line with Prior Year and 29,0% CORE EBITDA Margin

In 2024, Lonza delivered sales of CHF 6,6 billion in line with prior year (-0,2% CER1) CORE EBITDA of CHF 1,9 billion at a margin of 29,0% The CDMO2 business delivered a...

29 de ene. de 2025

Lonza erzielt für 2024 ein solides Ergebnis mit konstantem Umsatz und 29,0% Kern-EBITDA-Marge

Im Jahr 2024 erzielte Lonza einen Umsatz von CHF 6,6 Milliarden (-0,2% kWk1 gegenüber dem Vorjahr) Kern-EBITDA von CHF 1,9 Milliarden ergab eine Marge von 29,0% Das...

12 de dic. de 2024

Lonza Investor Update 2024 Outlines Strategy, New Organizational Structure and Guidance

Lonza has provided an overview of its new “One Lonza” strategy and new organizational structure

12 Nov 2024

Lonza to Expand Bioconjugation in Visp (CH) with Two Additional Manufacturing Suites

The expansion of bioconjugation capabilities will provide additional manufacturing capacity for launch and commercial supply, addressing growing market demand 2,000m2 of...

24 de oct. de 2024

Q3 2024 Qualitative Update: Lonza Confirms Full-Year Outlook 2024

Outlook 2024 confirmed: Flat year-on-year sales in CER and a CORE EBITDA margin of high 20s Strong commercial and operational performance across the CDMO business in...

22 de oct. de 2024

Lonza Extends Collaboration with Major Pharmaceutical Partner for Integrated Commercial Supply of Antibody-Drug Conjugates

Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC The...

03 de oct. de 2024

Lonza Nominates David Meline as Independent Board Member

David Meline brings extensive governance, financial and industry experience to Lonza’s Board of Directors Olivier Verscheure will not stand for re-election at the 2025 Annual...

01 de oct. de 2024

Lonza Completes Acquisition of Large-Scale Biologics Site in Vacaville (US) from Roche

The Vacaville site is one of the largest biologics manufacturing facilities in the world Acquisition extends Lonza’s US Biologics footprint with a significant presence on the...

24 de sep. de 2024

Lonza and Vertex Sign a Long-Term Commercial Supply Agreement for CASGEVY® (exagamglogene autotemcel)

Lonza to manufacture CASGEVY®, the world’s first CRISPR/Cas9 gene-edited cell therapy, for global commercial supply CASGEVY® will be manufactured at Lonza’s Geleen (NL) cell...

28 Aug 2024

Lonza Prices EUR 1,2 Billion Dual-Tranche Straight Bonds

Basel, Switzerland, 28 August 2024 – Lonza Finance International NV, a wholly owned company of Lonza Group Ltd, Basel (“Lonza”), announced today the pricing of its dual tranche...

25 Jul 2024

Lonza Nominates Juan Andres and Eric Drapé as Independent Board Members

Today, the Lonza Board of Directors announced the nomination of Juan Andres and Eric Drapé as Independent Members of the Board. The Board will propose to shareholders the election of both nominees at the Lonza Group Annual General Meeting (AGM) in May 202...

25 Jul 2024

Lonza Group H1 2024 Performance Well On Track to Deliver Full-Year Outlook: Sales Up 1,8% CER and 29,2% CORE EBITDA Margin

Lonza has reported sales of CHF 3,1 billion, growing 1,8% CER (-0,7% AER). CHF 893 million CORE EBITDA resulted in a robust margin of 29,2%, supported by favorable product mix and sustained demand for commercial CDMO services.

25 Jul 2024

2024 Halbjahresperformance der Lonza Gruppe in Übereinstimmung mit Gesamt-jahresprognose: Umsatzwachstum von 1,8% kWk und 29,2% Kern-EBITDA-Marge

Lonza verzeichnete einen Umsatz von CHF 3,1 Milliarden, was einer Umsatzsteigerung von 1,8% in konstanten Wechselkursen (kWk) (-0,7% AER)2 entspricht. Das Kern-EBITDA von CHF 893 Millionen führte zu einer robusten Marge von 29,2%, unterstützt von einer an...

01 Jul 2024

Lonza Welcomes New Group Chief Executive Officer Wolfgang Wienand

Wolfgang Wienand commences his tenure as Chief Executive Officer of Lonza Group Albert M. Baehny will retire from Lonza Group following a transition period Basel, Switzerland,...

24 de jun. de 2024

Lonza to Enhance Governance with Updates to its Board Committee Structure

Today, the Lonza Board of Directors has announced a series of updates, which will take effect on 1 August 2024.

14 de may. de 2024

Q1 2024 Qualitative Update: Performance In Line with Expectations for Full-Year 2024

Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s Softer performance in Q1 2024, normalizing across H1 2024 Sustained commercial demand in CDMO...

08 de may. de 2024

Lonza Announces Results of the 2024 Annual General Meeting – All Motions Proposed by Board of Directors Approved

Jean-Marc Huët was elected as Chairman of the Board of Directors Shareholders re-elected all members of the Board of Directors standing for re-election A dividend of CHF 4,00...